Obstructive Sleep Apnea Market Analysis, Size, Share & Growth Forecast 2026–2034

Tirzepatide SURMOUNT-OSA 55 to 62 Percent AHI Reduction in Obese OSA Patients at 52 Weeks Has Provided the First Pharmacological OSA Treatment With Meaningful AHI Reduction by Targeting the Obesity-Related Upper Airway Fat Deposition That GLP-1 Weight Loss Reduces.Eli Lilly's SURMOUNT-OSA trials demonstrated 25-29 event reduction per hour in the Apnoea-Hypopnoea Index for tirzepatide versus placebo in obese OSA patients, with a substantial fraction of patients achieving AHI normalisation below 5 events per hour that would represent clinical resolution of OSA. The weight loss mechanism accounts for most of the OSA benefit through reduction of peripharyngeal fat that narrows the upper airway and increases collapsibility during sleep, establishing body weight as the modifiable risk factor that drug therapy can target in a condition previously managed only with CPAP mechanical therapy or mandibular advancement devices. Regulatory approval for OSA as a distinct indication from obesity expands tirzepatide's prescribing base to pulmonologists and sleep medicine specialists who manage OSA independently from obesity, diversifying the prescriber base beyond endocrinology and primary care.

Inspire Medical Hypoglossal Nerve Stimulator STAR Trial 5-Year 67 Percent AHI Reduction in CPAP-Intolerant Moderate-to-Severe OSA Has Established the Upper Airway Stimulation as the Surgical Alternative That Provides Long-Term OSA Control for the Patient Who Cannot Use CPAP.Inspire Medical's hypoglossal nerve stimulator demonstrated 68% reduction in AHI at 12 months in STAR trial with sustained benefit at five years, providing a patient-controlled surgical alternative for the approximately 50% of OSA patients who are unable to tolerate the nightly CPAP mask and are ineligible for maxillomandibular advancement surgery. The device delivers synchronised phasic stimulation to the hypoglossal nerve during inspiration based on thoracic impedance sensing, activating genioglossus muscles that protrude the tongue and maintain airway patency during sleep without disrupting natural breathing patterns. Commercial revenue exceeded USD 700 million in 2024 as CPAP failure became recognised as an appropriate indication for UAS implantation, and expanded indications to patients with complete concentric collapse on drug-induced sleep endoscopy are being pursued through follow-on clinical programmes.

ResMed myAir Cloud-Connected CPAP Adherence Monitoring Enabling Remote AHI, Leak, and Usage Data Without Face-to-Face Troubleshooting Has Provided the Digital Health Platform That Improves CPAP Adherence Through Remote Identification and Correction of the Technical Issues Reducing Compliance.Approximately 50% of prescribed CPAP patients use the device fewer than 4 hours per night on fewer than 70% of nights, leaving the majority of OSA patients sub-therapeutically treated despite prescription and initiation. Positional OSA, defined as AHI at least twice as high in supine position as non-supine, represents approximately 50-60% of OSA patients, and positional therapy devices including NightBalance Lunoa from Philips and Night Shift from Advanced Brain Monitoring that prevent supine sleep demonstrate AHI reduction equivalent to CPAP in position-dependent OSA. Mandibular advancement devices from SomnoMed and ResMed provide a patient-preferred alternative to CPAP with adherence rates of 75-80% that exceed CPAP adherence but achieve less complete AHI normalisation, creating a clinical trade-off between perfect therapy poorly tolerated and imperfect therapy well adhered.

For related market intelligence, see the Cpap Market.